AGENUS INC (AGEN) - Dilution Analysis

10-Q filing | 38.3M shares outstanding

10-K filing | 38.4M shares outstanding

8-K filing: Agenus Inc. completed the sale of assets to Zydus Pharmaceuticals and Zynext Ventures purchased 2,133,333 shares of Agenus' common stock for $16.0 million. ($16.0M proceeds)

10-Q filing | 32.9M shares outstanding

8-K filing: Agenus Inc. entered into a Promissory Note Agreement with Zydus Pharmaceuticals for up to $10,000,000, collateralized by 822,910 shares of MiNK Therapeutics common stock owned by Agenus.

10-Q filing | 31.9M shares outstanding

8-K filing: Agenus Inc. entered into an Asset Purchase Agreement with Zydus Pharmaceuticals (USA) Inc. for the sale of its manufacturing operations assets, and a Securities Purchase Agreement with Zynext Ventures USA LLC for the sale of 2,133,333 shares of common stock at $7.50 per share for an aggregate purchase price of approximately $16.0 million. ($16.0M proceeds)

10-Q filing | 27.4M shares outstanding

S-3 filing: Agenus Inc. is offering 165,000 shares of common stock issuable upon the exercise of certain warrants by selling stockholders.

10-K filing | 25.3M shares outstanding

8-K filing: Agenus Inc. amended notes and warrants with existing noteholders, extending maturity dates, increasing interest rates, and issuing new warrants to purchase 67,500 shares of common stock at $3.25 per share.

8-K filing: A subsidiary of Agenus Inc. entered into a promissory note with Ocean 1181 LLC for a $22,000,000 loan, with interest payable partly in the Company's common stock, and at closing, the Company paid the Lender 153,003 shares of common stock.

10-Q filing | 21.6M shares outstanding

10-Q filing | 21.1M shares outstanding

10-Q filing | 20.4M shares outstanding

8-K filing: Agenus Inc. sold certain royalty rights to Ligand Pharmaceuticals for $75 million and issued a warrant to Ligand to purchase 867,052 shares of Agenus' common stock at an exercise price of $17.30.

POS AM filing: Agenus Inc. may offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, warrants, debt securities, or units consisting of any combination of the foregoing securities.

10-K filing | 418.9M shares outstanding

10-Q filing | 381.5M shares outstanding

10-Q filing | 379.6M shares outstanding

10-Q filing | 348.9M shares outstanding

8-K filing: Agenus Inc. declared a stock dividend of 5,000,000 shares of MiNK Therapeutics, Inc. common stock to be distributed to record holders of Agenus Inc.'s common stock as of April 17, 2023, with a distribution ratio of 0.0146 of a share of MiNK Common Stock for each share of Agenus Inc. Common Stock held on the Record Date.

10-K filing | 332.5M shares outstanding

8-K filing: Agenus Inc. amended notes and issued new warrants to existing noteholders, including warrants to purchase 1,300,000 shares expiring February 20, 2026 and 650,000 shares expiring February 20, 2028, all with an exercise price of $2.84 per share.

10-Q filing | 304.8M shares outstanding

10-Q filing | 283.2M shares outstanding

10-Q filing | 271.0M shares outstanding

10-K filing | 257.2M shares outstanding

10-Q filing | 256.8M shares outstanding

10-Q filing | 233.1M shares outstanding

10-Q filing | 222.4M shares outstanding

10-K filing | 204.7M shares outstanding

10-Q filing | 190.1M shares outstanding

10-Q filing | 183.4M shares outstanding

10-Q filing | 169.8M shares outstanding

10-K filing | 161.6M shares outstanding